Funds and ETFs Evolus, Inc.

Equities

EOLS

US30052C1071

Pharmaceuticals

Real-time Estimate Cboe BZX 10:43:36 2024-04-29 am EDT 5-day change 1st Jan Change
11.67 USD +2.10% Intraday chart for Evolus, Inc. +0.90% +12.30%

ETFs positioned on Evolus, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.00% 9 M€ +6.26% -
0.00% 147 M€ +4.88% -
0.00% 18 M€ +3.15% -
0.00% 34 M€ +2.79% -
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.43 USD
Average target price
22.29 USD
Spread / Average Target
+94.98%
Consensus
  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. Funds and ETFs Evolus, Inc.